Security
Forte Biosciences, Inc. Common Stock · FBRX
FBRXNASDAQCommon stockHistorical · closed Aug 27, 2026CIK 1419041Updated Oct 6, 2026
Name history
Tocagen Inc · through Jun 15, 2020
FBRX price & chart
Historical security
This listing closed Aug 27, 2026. Live provider charts are shown only for current listings.
About the company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).
In the news
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 97,089,000Source | 17,946,000Source | 205,743,000Source | 107,783,000Source | 26,078,000Source | 67,223,000Source | 47,459,000Source | 32,017,000Source | 82,779,000Source | 61,561,000Source | 38,980,000Source | 41,997,000Source |
| Property, Plant and Equipment, NetUSD | 148,000Source | 86,000Source | 90,000Source | 110,000Source | 96,000Source | 110,000Source | 125,000Source | 106,000Source | 129,000Source | 77,000Source | 109,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 93,414,000Source | 16,363,000Source | 49,629,000Source | 106,144,000Source | 24,498,000Source | 58,223,000Source | 45,856,000Source | 30,444,000Source | 76,957,000Source | 22,244,000Source | 37,125,000Source | 41,100,000Source |
| Assets, CurrentUSD | 95,412,000Source | 17,668,000Source | 203,103,000Source | 107,616,000Source | 25,711,000Source | 65,110,000Source | 47,158,000Source | 31,502,000Source | 80,589,000Source | 61,346,000Source | 38,327,000Source | 41,511,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,998,000Source | 1,305,000Source | 4,643,000Source | 1,472,000Source | 1,213,000Source | 6,887,000Source | 1,302,000Source | 1,058,000Source | 3,632,000Source | 2,981,000Source | 1,202,000Source | 411,000Source |
| Other Assets, NoncurrentUSD | 1,529,000Source | 192,000Source | 2,550,000Source | 57,000Source | 271,000Source | 2,003,000Source | 176,000Source | 409,000Source | 2,061,000Source | 138,000Source | 544,000Source | 486,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | — | 21,949,000Source | — | — | 25,123,000Source | — | — | 21,788,000Source | — | — | — |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 13,000Source | 1,000Source | 21,000Source | 12,000Source | 36,000Source | 14,000Source | 6,000Source | 36,000Source | 13,000Source | 6,000Source | 36,000Source | 21,000Source |
| Retained Earnings (Accumulated Deficit)USD | -198,585,000Source | -146,843,000Source | -268,840,000Source | -180,903,000Source | -138,451,000Source | -245,509,000Source | -169,654,000Source | -125,940,000Source | -223,373,000Source | -153,998,000Source | -118,520,000Source | -87,044,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -6,000Source | 1,000Source | -54,000Source | — | -7,000Source | -4,000Source | — | -2,000Source | 3,000Source | 11,000Source | 4,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 84,097,000Source | 9,366,000Source | 183,794,000Source | 98,613,000Source | 16,961,000Source | 42,100,000Source | 38,427,000Source | 28,685,000Source | 60,991,000Source | 52,480,000Source | 35,314,000Source | 38,818,000Source |
| Additional Paid in Capital, Common StockUSD | 282,675,000Source | 156,207,000Source | 452,667,000Source | 279,504,000Source | 155,383,000Source | 287,599,000Source | 208,075,000Source | 154,591,000Source | 284,348,000Source | 206,461,000Source | 153,794,000Source | 125,841,000Source |
| Liabilities and EquityUSD | 97,089,000Source | 17,946,000Source | 205,743,000Source | 107,783,000Source | 26,078,000Source | 67,223,000Source | 47,459,000Source | 32,017,000Source | 82,779,000Source | 61,561,000Source | 38,980,000Source | 41,997,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 12,992,000Source | 8,580,000Source | 20,289,000Source | 9,170,000Source | 9,117,000Source | 23,647,000Source | 9,032,000Source | 3,332,000Source | 20,751,000Source | 9,081,000Source | 3,666,000Source | 3,179,000Source |
| Accounts Payable, CurrentUSD | 5,491,000Source | 5,159,000Source | 14,010,000Source | 5,301,000Source | 5,275,000Source | 13,084,000Source | 5,023,000Source | 1,685,000Source | 9,989,000Source | 4,879,000Source | 1,424,000Source | 1,153,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,501,000Source | 3,421,000Source | 6,279,000Source | 3,869,000Source | 3,842,000Source | 10,563,000Source | 4,009,000Source | 1,647,000Source | 10,762,000Source | 4,202,000Source | 2,242,000Source | 2,026,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 198,500,000Source | — | — | — | — | — | — | 58,400,000Source | — | — |
| Short-term InvestmentsUSD | — | — | 148,831,000Source | — | — | — | — | — | — | 36,121,000Source | — | — |
| Other Liabilities, Noncurrent | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -22,136,000Source | -15,656,000Source | -69,375,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,177,000Source | 1,620,000Source | 6,258,000Source | 3,095,000Source | 3,284,000Source | 4,015,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 3,095,000Source | 578,000Source | 5,543,000Source | 3,021,000Source | 271,000Source | 207,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -18,808,000Source | -10,355,000Source | -50,882,000Source | -30,745,000Source | -28,706,000Source | -8,185,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 36,289,000Source | 36,234,000Source | -35,993,000Source | 47,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 61,000Source | 116,000Source | 37,000Source | 88,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 74,000Source | -2,322,000Source | 69,361,000Source | 51,857,000Source | 24,684,000Source | 7,241,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -18,734,000Source | 23,612,000Source | 54,713,000Source | -14,881,000Source | -3,975,000Source | -944,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 93,414,000Source | 16,363,000Source | 49,629,000Source | 106,144,000Source | 58,223,000Source | 45,856,000Source | 76,957,000Source | 22,244,000Source | 37,125,000Source | 41,100,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,479,000Source | 791,000Source | 3,666,000Source | 1,495,000Source | 3,177,000Source | 1,620,000Source | 6,258,000Source | 3,095,000Source | 3,284,000Source | 4,015,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | 198,500,000Source | — | — | — | — | 58,400,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 19,000Source | 13,000Source | 64,000Source | 39,000Source | 9,000Source | — |
| General and Administrative ExpenseUSD | — | — | 3,183,000Source | 2,759,000Source | 2,267,000Source | 2,960,000Source | 1,969,000Source | 3,432,000Source | 12,410,000Source | 15,409,000Source | 10,624,000Source | 8,302,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 193,000Source | 0Source | 373,000Source | 0Source | 1,037,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,682,000Source | -8,392,000Source | -23,331,000Source | -11,249,000Source | -22,136,000Source | -15,656,000Source | -69,375,000Source | -35,478,000Source | -31,476,000Source | -13,879,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 2,319,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 18,383,000Source | 8,629,000Source | 24,603,000Source | 11,579,000Source | 22,439,000Source | 16,124,000Source | 70,657,000Source | 36,602,000Source | 32,486,000Source | 13,896,000Source |
| Operating Lease, ExpenseUSD | — | — | 100,000Source | 79,000Source | 155,000Source | 96,000Source | 167,000Source | 97,000Source | 408,000Source | 300,000Source | 129,000Source | 19,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 701,000Source | 237,000Source | 1,465,000Source | 330,000Source | 676,000Source | 468,000Source | -396,000Source | -190,000Source | -114,000Source | 17,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | 0Source | 2,316,000Source | 7,441,000Source | 1,121,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 1,779,000Source | — | — | 7,229,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | -6,000Source | 8,000Source | -50,000Source | — | -7,000Source | -11,000Source | -8,000Source | 7,000Source | 4,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -18,383,000Source | -8,629,000Source | -24,603,000Source | -11,579,000Source | -22,439,000Source | -16,124,000Source | -70,657,000Source | -36,602,000Source | -32,486,000Source | -13,896,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 701,000Source | 237,000Source | 1,465,000Source | 330,000Source | 676,000Source | 468,000Source | -396,000Source | -190,000Source | -114,000Source | 17,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | -23,138,000Source | -11,249,000Source | -21,763,000Source | -15,656,000Source | -68,338,000Source | -35,478,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 193,000Source | 0Source | 373,000Source | 0Source | 1,037,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,682,000Source | -8,392,000Source | -23,331,000Source | -11,249,000Source | -22,136,000Source | -15,656,000Source | -69,375,000Source | -35,478,000Source | -31,476,000Source | -13,879,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.99Source | -4.54Source | -0.97Source | -0.96Source | -1.24Source | -1.37Source | -4.71Source | -12.17Source | -1Source | -0.8Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.99Source | -4.54Source | -0.97Source | -0.96Source | -1.24Source | -1.37Source | -4.71Source | -12.17Source | -1Source | -0.8Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | — | — | — | — | — | — | — | 17,383,531Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | — | — | — | 17,383,531Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,037,000Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 3,183,000Source | 2,759,000Source | 2,267,000Source | 2,960,000Source | 1,969,000Source | 3,432,000Source | 12,410,000Source | 15,409,000Source | 10,624,000Source | 8,302,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -72,485,000Source | -30,905,000Source | — | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | 2,715,000Source | 1,314,000Source | 1,124,000Source | — |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | 2,319,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 18,383,000Source | 8,629,000Source | 24,603,000Source | 11,579,000Source | 22,439,000Source | 16,124,000Source | 70,657,000Source | 36,602,000Source | 32,486,000Source | 13,896,000Source |
| Operating Lease, ExpenseUSD | — | — | 100,000Source | 79,000Source | 155,000Source | 96,000Source | 167,000Source | 97,000Source | 408,000Source | 300,000Source | 129,000Source | 19,000Source |
Offerings
Registration 333-224880
Registration 333-256611
Registration 333-283814
Registration 333-286226
Registration 333-296425
Filing attachments
ny20079488x1_ex107.htm · SC TO-T · 2026-08-06
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) ARGENX SE ( Exact Name of Registrant as Specified in its Charter ) Table 1 - Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee ──────────────────────────────────────────────────────────────────────────────────────────────────── Fees to be Paid $2,168,100,342.75 0.00013810 $299,414.66 Fees Previously Paid Tota…
Read attachment ↗tm2621326d3_ex99-1.htm · SC TO-C · 2026-07-28
Exhibit 99.1 argenx Business Update | 27th July, 2026 Moderator: Good morning. My name is Leila and I will be your conference operator today. I would like to welcome everyone to the call. At this time, all lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question and answer session. Thank you. I’d like to introduce Beth DelGiacco, Vice President of Corporate Affairs. You may now begin your call. Beth DelGiacco: Thank you Leila, an…
Read attachment ↗d135892dex991.htm · SC14D9C · 2026-07-27
Exhibit 99.1 Dear colleagues, Today, we announced that Forte has entered into an agreement to be acquired by argenx. You can read the full announcement here: [link to transaction press release]. While I understand this news may come as a surprise, I am genuinely energized by it. I believe this agreement is a testament to the promise of FB102 to treat celiac disease and vitiligo. The argenx team is enthusiastic about bringing FB102 into their growth plans and expanding their leadership in auto…
Read attachment ↗d31466dex991.htm · 8-K · 2026-07-27
EX-99.1 4 d31466dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases wit…
Read attachment ↗tm2621326d2_ex99-1.htm · SC TO-C · 2026-07-27
Exhibit 99.1 argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation …
Read attachment ↗tm2621326d2_ex99-2.htm · SC TO-C · 2026-07-27
Exhibit 99.2 argenx to Acquire Forte Biosciences STRATEGIC ANNOUNCEMENT JULY 27, 2026 Forward - Looking Statements Additional Information and Where to Find It The tender offer has not yet commenced. This document is for informational purposes only and is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any securities of Forte Biosciences, Inc. (Forte) or any other entity, nor is it a substitute for any tender offer materials that argenx, Avena Merger Su…
Read attachment ↗